ethyl 4-{[(E)-(4-methoxyphenyl)methylidene]amino}benzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-{[(E)-(4-methoxyphenyl)methylidene]amino}benzoate
• 化学式: C₁₇H₁₇NO₃
• 分子量: 283.327
• InChiKey: FCDJQSCCAKVJQM-LDADJPATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.62
• 重原子数：
  21.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  47.89
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  ethyl 4-{[(E)-(4-methoxyphenyl)methylidene]amino}benzoate 、 二乙基偶氮二羧酸酯 以36%的产率得到
  参考文献：
  名称：

  LEARDINI, RINO;NANNI, DANIELE;TUNDO, ANTONIO;ZANARDI, GIUSEPPE, J. CHEM. SOC. CHEM. COMMUN. ,(1989) N2, C. 757-758

  摘要：

  DOI：
• 作为产物：
  描述：

  苯佐卡因 、 4-甲氧基苯甲醛 以65%的产率得到
  参考文献：
  名称：

  ROBERT, J.;BOUCHERLE, A.;LUU-DUC, C., J. PHARM. BELG., 44,(1989) N, C. 36-40

  摘要：

  DOI：

文献信息

• Homolytic annulation by reaction of imidoyl radicals with diethyl azodicarboxylate: a new route to nitrogen heterocycle derivatives
  作者：Rino Leardini、Daniele Nanni、Antonio Tundo、Giuseppe Zanardi

  DOI：10.1039/c39890000757

  日期：——

  An easily effected aromatic annulation is described, involving the reaction of arylimidoyl radicals with diethyl azodicarboxylate to give 1,2-dihydro-1,2-dihydro-1,2-diethoxycarbonyl-benzo- and -pyrido-1,2,4-triazines.

  描述了一种易于实现的芳族环化反应，涉及芳基酰亚胺基与偶氮二羧酸二乙酯的反应，生成1,2-二氢-1,2-二氢-1,2-二乙氧基羰基-苯并-和吡啶-1,2,4-三嗪。
• BHAT, A. R.;SHETTY, SATISH, INDIAN J. PHARM. SCI., 49,(1987) N 5, 194-197
  作者：BHAT, A. R.、SHETTY, SATISH

  DOI：——

  日期：——
• METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS
  申请人：Srivastava Rakesh K.

  公开号：US20080214547A1

  公开（公告）日：2008-09-04

  This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
• US7915245B2
  申请人：——

  公开号：US7915245B2

  公开（公告）日：2011-03-29